Latest Conference Articles

Recent years have seen calls for genetic testing for all patients with breast cancer. A session at the 2020 San Antonio Breast Cancer Symposium reviewed the evidence for, and against, such testing.

Hope Rugo, MD, director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the benefits of oral paclitaxel in metastatic breast cancer.

Gregory Vidal, MD, PhD, West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in HER2-positive breast cancer.

A spotlight poster discussion at SABCS highlighted topics in genomic testing, potentially game-changing therapies, and predictive biomarkers in HR-positive breast cancer.

Poster presentations at the San Antonio Breast Cancer Symposium demonstrated the clinical relevance and efficacy of oral paclitaxel plus encequidar in the treatment of metastatic breast cancer.

Lee Schwartzberg, MD, FACP, chief medical director of West Cancer Center and chief medical officer of OneOncology, discusses the approvals of pembrolizumab and sacituzumab govitecan for patients with triple-negative breast cancer.

During the San Antonio Breast Cancer Symposium 2020, Lajos Pusztai, MD, DPhil, of Yale Cancer Center, reviewed recently established and emerging biomarkers in both the neoadjuvant and metastatic breast cancer settings.

Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.

City of Hope's Joanne Mortimer, MD, a medical oncologist and director of the Women's Cancer Program, discusses a poster presentation from the 2020 San Antonio Breast Cancer Symposium.

A panel at the 2020 San Antonio Breast Cancer Symposium discussed 3 new drug approvals from the past year, highlighting changes in the treatment landscape across multiple breast cancer types.

Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.

The first session at the San Antonio Breast Cancer Symposium 2020 looked at how the COVID-19 pandemic is disproportionately affecting care for minority patients.

As more data have become available, we are seeing more and more patients receiving chimeric antigen receptor (CAR) T-cell therapy in the community setting, noted Karl Kilgore, PhD, senior research scientist at Avalere Health.

A late-breaking study presented at the American Society of Hematology annual meeting raises the specter of whether interventions can occur decades before a blood cancer would appear.

The treatment appeared to live up to its billing of having fewer off-target effects in studies presented at the American Society of Hematology.

Twelve-month maintenance data from this study demonstrate the survival and response benefits associated with daratumumab, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.

Zanubrutinib has a cleaner kinome than ibrutinib in that it hits fewer off-target kinases, said Ian Flinn, MD, PhD, director of lymphoma research at Sarah Cannon Research Institute.

Doctors who treated patients with sickle cell disease who received an infusion of gene-edited treatment have called it "transformative" for those who live with a chronic condition.

Three researchers presented results on COVID-19 therapies and data of importance to patients with hematological conditions.

Results were released for a leading chimeric antigen receptor (CAR) T-cell therapy candidate in multiple myeloma, along with long-term findings for an early treatment that may soon face competition.

There have been exceptional results seen in CARTITUDE-1, stated Deepu Madduri, MD, assistant professor at the Icahn School of Medicine at Mount Sinai in New York City and associate director of its cellular therapy program.

It’s important to get the medicine and the science right, but we must not lose sight of that human connection between patient and caregiver, emphasized Robert K. Massie, Jr, PhD, MA, of the Society for Progress. Massie will speak during the virtual ASH meeting.

The lead investigator touted the benefits of subcutaneous administration of daratumumab in relapsed multiple myeloma (MM) during a presentation on practice-changing results ahead of the American Society of Hematology annual meeting.

Adding daratumumab to standard-of-care regimens consistently improves outcomes among patients with multiple myeloma, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.

A preview of the 62nd annual American Society of Hematology meeting, taking place in a virtual format.

Investigators will be presenting exciting data on several treatments for multiple myeloma at the American Society of Hematology (ASH) meeting, noted Mark Wildgust, PhD, vice president of Global Medical Affairs/Oncology at Janssen.

At this year’s American Society of Hematology (ASH) meeting, we will see more on new and different targets we can utilize in myeloma, noted Deepu Madduri, MD, assistant professor at the Icahn School of Medicine in New York City and associate director of its cellular therapy program.

After recent setbacks, the beleaguered drug reduced cardiovascular events and may be a choice for patients with severe chronic kidney disease.

The investigator of the STRENGTH study says findings raise questions about the landmark REDUCE-IT trial, but other evidence suggests the drugs involved are different.

A registry study suggests 4 in 5 patients with heart failure might benefit from the SGLT2 inhibitor dapagliflozin.